PYXS
Pyxis Oncology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 30 ▼ 1 insider sell $107.1K at $3.06
- Aug 3 Wells Fargo initiates
- Sep 9 ▲ Pyxis Oncology announced positive updated Phase 1 monotherapy data f…
- Sep 30 ▼ Pyxis Oncology priced a public offering of 36M shares and 49.3M comm…
- Sep 30 Offering: Pyxis Oncology Announces Pricing of Up to $282.6 Million P…
- Oct 1 ▲ 1 insider buy $0.00
- Oct 1 ▼ Pyxis Oncology closed a ~$103M underwritten public offering on Octob…
- Oct 1 ▼ Pyxis Oncology priced a $110.0 million underwritten public offering…
- Oct 2 ▼ Pyxis Oncology closed a ~$110M public offering on October 1, 2026, s…
- Oct 2 Offering: Pyxis Oncology Announces Closing of Up to $282.6 Million P…
- Oct 21 ▼ Pyxis Oncology is holding a special meeting on November 13, 2026 to…
- Oct 27 FDA: Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Ph…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $107.1K.
- InstitutionsMIXED
Q3 2026: 12 added (1 new), 9 trimmed or exited.
- AnalystsBULLISH
14 of 16 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.278 → −$0.210 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +4.1% to 4.53M shares. 5.8 days to cover, ≈3.8% of shares.
- TrendDOWNTREND
38% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $9.3M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $939.2K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $856.9K |
| STATE STREET CORP | ADD | $765.0K |
| MACKENZIE FINANCIAL CORP | DOUBLED | $211.4K |
| BARCLAYS PLC | DOUBLED | $98.5K |
| JANE STREET GROUP, LLC | NEAR_EXIT | $76.1K |
| LPL Financial LLC | TRIM | $75.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +396%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 6, 2026 | Wedbush MAINTAIN | Outperform |
| Sep 10, 2026 | Wedbush MAINTAIN | Outperform |
| Sep 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 9, 2026 | Wells Fargo MAINTAIN | Overweight |
| Sep 9, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
HUMPHREY RACHEL Director Nov 6, 2026 | AWARD | 34,500 sh |
GordonMD Global Investments LP 10%+ Owner Oct 1, 2026 | BUY | 7,172,000 sh |
GordonMD Global Investments LP 10%+ Owner Oct 1, 2026 | BUY | 5,517,000 sh |
GordonMD Global Investments LP 10%+ Owner Oct 1, 2026 | BUY | 7,546,766 sh |
Civik Thomas CEO & Chairman of the Board Sep 4, 2026 | AWARD | 2,503,050 sh |
Dupont Jakob Director Aug 20, 2026 | AWARD | 46,000 sh |
Civik Thomas Interim CEO Aug 12, 2026 | AWARD | 250,956 sh |
Dupont Jakob Director Jun 30, 2026 | SELL | $107.1K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.21 | -$0.31–-$0.15 | +18.5% | $19.4K |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Aug 11, 2026 | Volatility Pause | Resumed |
| Aug 11, 2026 | Volatility Pause | Resumed |
| Aug 11, 2026 | Volatility Pause | Resumed |
| Aug 11, 2026 | Volatility Pause | Resumed |
SecBot reports
19 filings · 6 press releases · 1 bullish · 5 bearish · 2 mixed · 11 neutral- NEUTRAL SC 13GNov 16, 2026
OrbiMed Advisors LLC and OrbiMed Capital LLC filed a Schedule 13G disclosing aggregate beneficial ownership of 7.0% of Pyxis Oncology common stock as of September 30, 2026. This is a new passive stake filing by a healthcare-focused investment firm, adding to the recent cluster of large passive…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Biotechnology Value Fund L.P. (BVF) and affiliated entities filed an amended Schedule 13G disclosing an aggregate beneficial ownership of 11,945,583 shares (9.99%) of Pyxis Oncology as of September 30, 2026, up from a prior 9.9% stake reported by RTW Investments on the same date. The filing…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 16, 2026
RTW Investments, LP disclosed a new 9.9% passive stake in Pyxis Oncology as of September 30, 2026, consisting of 8,535,153 shares (including 2,028,924 warrant shares subject to a 9.99% blocker). This is a new filing by RTW, not an amendment, and the stake is sizable at nearly 10% of shares…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 5, 2026
Pyxis Oncology reported Q3 2026 net loss of $20.0M ($0.24 per share), narrower than the $22.0M…
The Phase 3 Headliner trial design alignment with FDA/EMA is the key catalyst path; watch for FDA dose selection feedback in Q1 2027 and the December 2026 corporate update with combination data. The…
All PYXS filing & press-release reports (25)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 16, 2026
- 8-K reportNov 5, 2026
- SC 13G/A reportNov 3, 2026
- PRESS-RELEASE reportOct 27, 2026
- DEF 14A reportOct 21, 2026
- SC 13G/A reportOct 9, 2026
- SC 13G/A reportOct 2, 2026
- PRESS-RELEASE reportOct 2, 2026
- 8-K reportOct 1, 2026
- 424B5 reportOct 1, 2026
- PRESS-RELEASE reportSep 30, 2026
- 8-K reportSep 8, 2026
- 8-K reportSep 9, 2026
- EFFECT reportAug 28, 2026
- 8-K reportAug 13, 2026
- 144 reportJun 30, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 30, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 23, 2026